Other studies have pointed out that the use of OV armed with PD-L1 blocking mini-antibody (Tanoue et al., 2017) or IL12p70 and PD-L1 (Rosewell Shaw et al., 2017), combined with CAR-T cell therapy is more effective for tumor control and prolonged survival when compared to each agent as monotherapy. This evidence concerns the gene CD274 and neoplasm.